High-yield points
- Four groups: WNT, SHH, Group 3, Group 4 .
- WHO 2021: WNT-activated; SHH TP53-wildtype; SHH TP53-mutant; non-WNT/non-SHH .
- Histology (classic, desmoplastic/nodular, MBEN, large cell/anaplastic) is now a morphologic pattern .
- WNT:
- CTNNB1 mutation and monosomy 6.
- Over 90% survival.
- A candidate for therapy de-escalation .
- SHH:
- Infants and adults; PTCH1, SUFU, SMO.
- TP53 mutation means very high risk (41% 5-year OS) and is often germline .
- Group 3:
- MYC amplification; often metastatic.
- Worst outcome. Metastatic Group 3 is very high risk .
- Group 4:
- The most common group (about 46%); i17q.
- Non-metastatic with chromosome 11 loss or 17 gain is low risk .
- Genetics referral: test germline in all WNT and SHH tumors .
Landmark papers
- 2010 consensus (Taylor et al., Acta Neuropathol 2012): defined four core groups, WNT, SHH, Group 3 and Group 4, by transcriptional profiling .
- 2015 risk-stratification consensus (Ramaswamy et al., Acta Neuropathol 2016): for ages 3–17, low-risk groups have survival over 90% (WNT; non-metastatic Group 4 with chromosome 11 loss or 17 gain) and high-risk groups 50–75% .
- SJMB03 (Gajjar et al., J Clin Oncol 2021): 330 patients aged 3–21 years. Combining molecular and clinical factors defined three low-risk groups, each with 5-year PFS over 90% .
Medulloblastoma is not one disease. Since a 2010 consensus, it has been divided into four molecular groups: WNT, SHH, Group 3 and Group 4. Each has its own genetics, ages, metastatic behavior and outcome . The 2021 WHO classification builds these groups into the diagnosis. Risk stratification now combines molecular group with the classic clinical factors: age, metastases and extent of resection .
Classification
- 2010 consensus: four core groups :
- WNT, SHH, Group 3 and Group 4.
- They were defined by transcriptional profiling and differ in demographics, genetics and outcome.
- 2021 WHO classification (CNS5) :
- Molecularly defined types:
- Medulloblastoma, WNT-activated.
- Medulloblastoma, SHH-activated and TP53-wildtype.
- Medulloblastoma, SHH-activated and TP53-mutant.
- Medulloblastoma, non-WNT/non-SHH, comprising Groups 3 and 4.
- "Medulloblastoma, histologically defined": the morphologic patterns are now patterns of a single inclusive tumor type rather than separate types:
- classic;
- desmoplastic/nodular;
- medulloblastoma with extensive nodularity (MBEN);
- large cell/anaplastic.
- Morphology tracks molecular group:
- Desmoplastic/nodular tumors and MBEN align with SHH.
- Nearly all WNT tumors are classic.
- Reporting: use a layered, integrated diagnosis. Methylome profiling helps designate subtypes.
- Grade: every medulloblastoma is CNS WHO grade 4. WHO notes this "risks giving a false sense of prognosis" for WNT tumors.
- Second-generation subtypes (below the four groups):
- WHO 2021: recognizes 4 SHH subgroups and 8 non-WNT/non-SHH subgroups. The infant subgroups SHH-1 and SHH-2 differ in outcome .
- 12 subtypes overall: an integrative analysis of 763 tumors (methylation, expression and copy number) identified 12, including two infant SHH subtypes with different outcomes .
- Group 3/4 subtypes I–VIII: a meta-analysis of 1,501 tumors defined eight robust subtypes with very different survival .
The four groups
- WNT :
- Genetics: CTNNB1 mutation (96%), monosomy 6. Also DDX3X (37%) and SMARCA4 (24%).
- Age and sex: children and adults, uncommon in infants. The sex ratio is about 1:1.
- Metastases: 9% at diagnosis.
- Prognosis: long-term survival likely above 90%. Deaths are more often from treatment complications or second cancers than from recurrence. 5- and 10-year OS was 95% in children.
- SHH :
- Genetics: PTCH1 (38%), TP53 (21%), DDX3X (19%). The pathway also includes SUFU and SMO. MYCN amplification occurs here.
- Age: bimodal. Common in infants (0–3) and adults (over 16), less common in children.
- Histology: desmoplastic histology in infants carries a very good outcome (5- and 10-year OS 84%) .
- Group 3 :
- Genetics: MYC amplification is almost confined to Group 3 (24 of 27 MYC-amplified tumors). Isochromosome 17q occurs in 26%.
- Age and sex: infants and children, almost never adults. More common in males.
- Histology and spread: often large cell/anaplastic, and often metastatic (30% at diagnosis).
- Prognosis: the worst. 5-year OS was 58% in children and 45% in infants.
- Group 4 :
- Frequency: the most common group.
- The prototype: "a 7-year-old boy with a classic histology medulloblastoma that has an isochromosome 17q."
- Genetics: isochromosome 17q is its most common change (66%).
- Metastases: 31% at diagnosis.
- Prognosis: intermediate.
- Frequency in a prospective trial (SJMB03, ages 3–21, methylome): WNT 17.4%, SHH 15.7%, Group 3 21.3%, Group 4 45.6% .
Prognostic implications
- 2015 consensus risk groups (ages 3–17, non-infant) :
- Low risk (survival over 90%):
- WNT.
- Non-metastatic Group 4 with whole chromosome 11 loss or whole chromosome 17 gain.
- These may qualify for reduced therapy.
- Average risk: 75–90% survival.
- High risk (50–75%):
- Metastatic SHH or Group 4.
- MYCN-amplified SHH.
- Very high risk (under 50%):
- Metastatic Group 3.
- SHH with TP53 mutation.
- SJMB03 (330 patients, 3–21 years) :
- By clinical risk: 5-year PFS was 83.2% (average risk) vs. 58.7% (high risk).
- By clinicomolecular risk: combining molecular and clinical factors defined three low-risk groups, each with 5-year PFS over 90%:
- WNT;
- low-risk SHH;
- low-risk Groups 3/4.
- It also defined two very high-risk groups with 5-year PFS under 60%.
- TP53 in SHH is the key adverse marker :
- TP53 mutation in SHH: 5-year OS was 41% vs. 81% without it.
- It accounted for 72% of deaths in children over 5 with SHH tumors.
- In WNT tumors, TP53 mutation did not worsen outcome (90% vs. 97%, not significant).
- Age: SHH/TP53-mutant patients are almost all aged 5–18.
- Germline: 56% of these mutations are germline (Li–Fraumeni).
- MYC or MYCN amplification predicted worse outcome overall and within subgroups. The exception was Group 3, where non-amplified tumors also did poorly .
- Histology still matters: large cell/anaplastic histology predicted poor outcome in every age group (5-year OS 22% in infants) .
- Further refinement:
- Group 3 and Group 4 each split into high- and low-risk subgroups.
- SHH split into infant (under 4.3 years) and childhood groups .
- Group 3/4 subtypes I–VIII have very different survival .
Germline predisposition
- Burden: about 5–6% of medulloblastomas are germline-driven, rising to 14–20% of SHH tumors .
- Consensus predisposition genes :
- APC: WNT tumors, including most WNT tumors without CTNNB1 mutation (Turcot).
- PTCH1 and SUFU: mostly infant SHH (Gorlin).
- TP53: childhood SHH (Li–Fraumeni). It explained more than half of the chromothripsis in SHH tumors.
- BRCA2 and PALB2: across SHH and Groups 3/4.
- Outcome: 5-year PFS was 52% in patients with a germline predisposition .
- Recommendation: offer genetic counseling and testing for all WNT and SHH medulloblastoma .
Targeted therapy
- SMO inhibition (vismodegib): active only against recurrent SHH medulloblastoma, mainly in adults .
- Response depends on where the mutation is: tumors with mutations downstream of SMO (for example, SUFU or GLI2) didn't respond.
- Children: pediatric accrual was too small to draw conclusions.
Related topics
- ATRT: the other major embryonal tumor of infants.
- Embryonal Brain Tumors: the other embryonal entities.
- Li-Fraumeni Syndrome: germline TP53 and SHH medulloblastoma.
- Gorlin Syndrome: PTCH1/SUFU predisposition.
- Ependymoma: the other common posterior fossa tumor.
- Posterior Fossa Tumor Resection: step-by-step procedure.
References
- Taylor MD, Northcott PA, Korshunov A, et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol 2012;123(4):465–472. doi:10.1007/s00401-011-0922-z. PMID 22134537. verified
- Kool M, Korshunov A, Remke M, et al. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol 2012;123(4):473–484. doi:10.1007/s00401-012-0958-8. PMID 22358457. verified
- Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 2021;23(8):1231–1251. doi:10.1093/neuonc/noab106. PMID 34185076. verified
- Ramaswamy V, Remke M, Bouffet E, et al. Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. Acta Neuropathol 2016;131(6):821–831. doi:10.1007/s00401-016-1569-6. PMID 27040285. verified
- Cavalli FMG, Remke M, Rampasek L, et al. Intertumoral heterogeneity within medulloblastoma subgroups. Cancer Cell 2017;31(6):737–754.e6. doi:10.1016/j.ccell.2017.05.005. PMID 28609654. verified
- Sharma T, Schwalbe EC, Williamson D, et al. Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes. Acta Neuropathol 2019;138(2):309–326. doi:10.1007/s00401-019-02020-0. PMID 31076851. verified
- Gajjar A, Robinson GW, Smith KS, et al. Outcomes by clinical and molecular features in children with medulloblastoma treated with risk-adapted therapy: results of an international phase III trial (SJMB03). J Clin Oncol 2021;39(7):822–835. doi:10.1200/JCO.20.01372. PMID 33405951. verified
- Zhukova N, Ramaswamy V, Remke M, et al. Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. J Clin Oncol 2013;31(23):2927–2935. doi:10.1200/JCO.2012.48.5052. PMID 23835706. verified
- Schwalbe EC, Lindsey JC, Nakjang S, et al. Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study. Lancet Oncol 2017;18(7):958–971. doi:10.1016/S1470-2045(17)30243-730243-7). PMID 28545823. verified
- Waszak SM, Northcott PA, Buchhalter I, et al. Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. Lancet Oncol 2018;19(6):785–798. doi:10.1016/S1470-2045(18)30242-030242-0). PMID 29753700. verified
- Robinson GW, Orr BA, Wu G, et al. Vismodegib exerts targeted efficacy against recurrent sonic hedgehog-subgroup medulloblastoma: results from phase II Pediatric Brain Tumor Consortium studies PBTC-025B and PBTC-032. J Clin Oncol 2015;33(24):2646–2654. doi:10.1200/JCO.2014.60.1591. PMID 26169613. verified
Verification (2026-11-11): each reference's authors, title, journal, volume, pages, DOI and PMID were checked on PubMed. Numbers were checked against the PubMed abstracts and, where needed, the open-access full texts:
- Reference 1 (PMC3306779): subgroup demographics, i17q frequencies, MYC in Group 3, the WNT prognosis.
- Reference 2 (PMC3306778): metastasis rates, survival by subgroup and age, MYC/MYCN distribution, histology outcomes.
- Reference 3: the 2021 WHO medulloblastoma types, morphology, subgroups and grading, from the full text (PMC8328013), read via a fetch agent.
Caveats:
- The syndrome names (Turcot, Gorlin, Li–Fraumeni) are standard associations for the genes reference 10 reports.
- Survival figures come from different cohorts and eras, and are not directly comparable.
- Reference 11's statement about mutations downstream of SMO is from the abstract (4 of 4 non-responders). The SUFU/GLI2 examples are added for context.
- The figure is an original summary graphic.